|Publication number||WO2000048532 A1|
|Publication date||24 Aug 2000|
|Filing date||17 Feb 2000|
|Priority date||18 Feb 1999|
|Also published as||US6746485|
|Publication number||PCT/2000/4054, PCT/US/0/004054, PCT/US/0/04054, PCT/US/2000/004054, PCT/US/2000/04054, PCT/US0/004054, PCT/US0/04054, PCT/US0004054, PCT/US004054, PCT/US2000/004054, PCT/US2000/04054, PCT/US2000004054, PCT/US200004054, WO 0048532 A1, WO 0048532A1, WO 2000/048532 A1, WO 2000048532 A1, WO 2000048532A1, WO-A1-0048532, WO-A1-2000048532, WO0048532 A1, WO0048532A1, WO2000/048532A1, WO2000048532 A1, WO2000048532A1|
|Inventors||James F. Zucherman, Ken Y. Hsu|
|Applicant||Zucherman James F, Hsu Ken Y|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (5), Referenced by (4), Classifications (27), Legal Events (6)|
|External Links: Patentscope, Espacenet|
HAIR USED AS A BIOLOGIC DISK, REPLACEMENT, AND/OR STRUCTURE AND METHOD
This application claims the benefit of U.S. Provisional Application No. 60/120,486, filed February 18, 1999, and Provisional Application No. 60/163,224, filed November 3, 1999.
Field of the Invention: The field of the invention relates to biologic disks, replacements, and/or structures principally for human and animal use.
Background of the Invention:
The normal human disk is made of multiple layers (13) of collagen and a highly hydrophilic mucopolysaccharide center. This is similar to a radial car tire. This construct converts compression axial loads on the gelatinous center to the outer collagen fibers as tensile forces. This tissue is highly viscoelastic. The construct provides both mobility and stability to the spinal joints. Unfortunately the chemical properties of the gelatinous center material (nucleus pulposis) deteriorate with age and become less hydrophilic. Forces are not converted from compression to tension as well and more compression and torsional loads are conferred to the outer layers (annulus). These layers deteriorate and lose their integrity forming multiple small tears, which coalesce and become large ones. T he disk loses height; material bulges or extrudes into inappropriate locations through ruptured annular walls. The grip on the vertebra slackens and chronic nerve stimulation occurs due to release of degenerated debris and loss of space for the nerves. Thus we have 80% of the population with significant disabling symptoms at some time in their lives from lumbar spine disease. The only ailment more common than back pain is the common cold.
In orthopedic surgery badly deteriorated joints are either fused together to control pain or joint replacement procedures are performed to control pain without complete loss of the motion function of the joint. Obviously the maintaining of as much of the normal motion in the joint as is possible is ideal. When joints are fused, adjacent joints must work much harder in compensation, and may become symptomatic also. In the lumbar spine there are five joints and the hips that share in the motion function so there is more forgiveness when one or more, but fewer than when all, are fused together. However, very often there are several deteriorated joints. Fusing too many joint results in such overload of adjacent joint structures that as many problems are created by fusing as are solved. The treatment of hip and knee arthritis has been absolutely revolutionized by joint replacement surgery. The spine is still in the dark ages because of no viable joint replacement procedure exists.
The spinal joint is actually three joints, two facet joints and one disk. The three joints interact to allow the right balance of mobility and stability for spine function as we know it. Research has shown that deterioration occurs first in the disk, and then as a consequence of changes in the facet joints. Therefore, replacing the disk function will halt deterioration of the entire joint complex.
Much work has been done in order to develop mechanical disk replacements. None have been shown to have lasting effectiveness. Problems associated with maintaining the location, size, wear, and fatigue failure have been the stumbling blocks for prior prototypes. Summary of the Invention:
A biologically compatible prosthesis will certainly be the future reality for disk replacement. Hair which is immunoiogically silent, strong, very modifiable and has the potential for biological incorporation is the answer. There are two components to the disk as mentioned above. These include the annulus and the nucleus pulposis. The former, in one embodiment, can be constructed similarly to a textile from autologous or homologous hair. The latter, in one embodiment, can be constructed by processing keratin sulfate or utilizing another substance such as a hydrophilic gel, poloyxymer 407, and/or regenerated in vivo by utilization of morphogenetic growth factors. Recombinant growth factors are being produced now and some do produce the same substances in the nucleus pulposis under appropriate conditions in vivo. One embodiment includes a "hair bag" inserted into the center of the human disk through a small incision and that is then filled with a gelatinous substance containing cartilage growth factors. As the body incorporates the tissue, the new somewhat similar "disk" forms within the deteriorated one. The tissue may be more fibrotic than normal, and have less elasticity than normal. This would nevertheless meet the goal of allowing motion and stability, and therefore greatly improve symptomatology.
Other aspects of the invention use hair as a biologic implant, replacement, and/or structure. Such implants can be cosmetic implants. Additional blood vessel replacements can be constructed from hair. Further, hair can be used for joint resurfacing or meniscal replacement. Still further, hair can be used as a biological endoprosthesis for ligament and tendons. Brief Description of the Figures:
Fig. 1 is a representation of an embodiment of the first artificial disk structure of the invention with a polymer retained in a sack. Fig. 1 is attached. Fig. 2 is a representation of an embodiment of the second artificial disk structure of the invention with a disk comprised of hair with the hair in the center of the artificial disk specially treated to model the complex polymer found in a natural disk. Fig. 2 is attached.
Fig. 3 is a representation of an embodiment of a cosmetic prosthesis for a nose.
Fig. 4 is an embodiment of a vascular graph of the invention.
Fig. 5 is an embodiment of a joint resurfacing graph of the invention.
Fig. 6 is an embodiment of a tendon or ligament graph of the invention.
Detailed Description of the Preferred Embodiment: First Artificial Disk Structure
For this embodiment (Fig. 1 ), a state-temperature dependent polymer can be injected as a liquid into the diseased intervertebral disk, and then can undergo a change to a solid viscoelastic state at body temperature, which can have similar properties as the normal intervertebral disk. The polymer can include, by way example, any one of the following polymers. These polymers include Poloxamer 407 and other Poloxamers, polymer combinations, and polypropylene. These polymers can be acquired under the trade names Poloxamer 407, Plannemic-Acid F127, from the following company: Sigma Aldrich. An outer covering to contain the artificial disk, which covering has sufficient tensile strength, will be necessary to maintain the disk height and prevent compression on the centrally injected polymer. Accordingly, a woven outer sack 10 can be used to reproduce the normal disks function. This sack 10 would need to be biocompatible to facilitate ingrowth of normal fibrous or fibrocartiliginous tissue, anchoring and melding the artificial disk with remnants of living disk tissue and/or the vertebral bone. Possible candidates for this outer sheath are various polymer compounds, and the recipients own hair processed to form a tightly woven fabric. The proteins in recipient's hair will not be subject to rejection phenomena and thus, be readily accepted by the recipient's immune system, a crucial factor for ingrowth to occur. Polymer materials which could be used to form the outer sack include: polypropylene, polylactic acid materials, polyesther polymer mesh, composites of collagen and BMP, titanium fiber with BMP with or without non-collagenase proteins, polydioxanone, poiyphosphazenes and BMP, ceramic collagen composite, expanded polytetrafluoroethylene barrier membranes, and ethylene-vinyl acetate copolymers in methylene chloride (Elvax 40).
These polymers are characterized as having the following (physical, mechanical, chemical, biomechanical) properties and ranges of properties: good tensile strength, low coefficient of elasticity, capacity for soft tissue in growth or replacement in vivo, binding affinity for BMP, TGF-Beta, and other bone, fibrous and cartilage tissue growth factors, resistance to fracture, and biocompatability. If the recipient's hair is used as the outer sack, such hair would be treated according to the following process. This process includes one or a combination of the following: Heparin SO4 treatment, dextran, protease, elastase, collagenase, guanidine hydrochloride and lithium bromide exposure. The hair would be woven or blended together using one of the following techniques. These techniques include: denaturation, acid treatment, loom and machine weaving.
After a portions or all of a dysfunctional disk is removed, the sack can be inserted in the inter-discal space. The disk material can be removed using a number to techniques currently on the market. Thereafter, the sack 10 can, by way of example only, be inserted through a cannula in a minimally invasive technique in order to position the sack in the space between two adjacent vertebral bodies. After this procedure is complete, the sack 10 can be injected and filled with the appropriate polymer 12 or other material. These materials can be state-dependant such that at one temperature, which is different than that of the body temperature of the patient, the materials flow more easily through a needle or cannula, and at about body temperature the materials become more able to support the weight along the spinal column. Thus the materials can become more viscous and resilient once attaining the temperature of the body of the patient.
As described above, in this embodiment, the sack is comprised of woven hair which is then filled with a polymer.
Second Artificial Disk Structure
For this embodiment (Fig. 2), a disk replacement 20 is made of processed hair entirely. The process for processing the hair is as follows. This process includes one or more of the following: steps of denaturation, collagenase, protease, heparin sulphate, and dextran exposure. The hair can then be woven together in a mass and inserted into the disk space using a variety of techniques including from open surgery to insertion through an appropriately sized cannula. The hair can be a matrix structure characterized and described as follows. The matrix structure can include a denaturation, reduction of disulfide bonds (cyanogen bromide) proteolysis. Although not required for this embodiment, augmentation with cartilage producing Bone Morphogenic Protein (BMP) can allow a new intervertebral disk to form with the hair based collagen matrix as the cartilage inductive morphogenic substances and biomechanical stresses in the intervertebral space can induce differentiation of a new living intervertebral disk. Such Bone Morphogenic Protein can include the following types BMP's 1-15, TGF-Beta, insulinlike growth factor, platelet derived growth factor. Additionally, the complex organic polymer which makes up much of the center of the normal disk and is responsible for its properties can be chemically created from hair and processed collagen to use as the central matrix of the artificial disk. A process for treating the hair based collagen matrix, in order to create the central nucleus of the artificial disk is as follows. This method includes one or more of the following steps of heparin sulphate or other polyanionic compound denaturation, and guanidine hydrochloride exposure. An outer woven hair bag would still be used in this case to confer the necessary biomechanical properties. This hair bag or sack can be constructed and have the properties of the sack previously described above. In this embodiment, the basic disk implant is comprised of multiple layers 22, 24, 26 of woven hair with each layer having a different orientation.
The chemical processing of hair to modify its structure for use as (i) a Morphogenic protein carrier, and to (ii) increase its flexibility so it can be used as a strong "net* for use as a annulus replacement is as follows: This process includes mechanical weaving, partial denaturation, heparin treatment, collagenase and proteolytic treatment. BMP (a cartilage and bone growth factor), in a particular embodiment can be carried by a product known as Poloxamer 407. The characteristics of this material are found in Table 1 below.
Pluracare® F 127 Prill CTFA/INCI: Poloxamer 407
Cloud Point (10% aqueous, °C) ≥ 100
Color (APHA) ≤ 120
Water Content (%) < 0.75 pH (2.5% aqueous) 6.0 to 7.4
Description Product Number
PluracareF 127 surfactant is a block 547427 copolymer of ethylene glycol and propyiene glycols
White solid in the form of small beads
Due to their low skin and eye irritation, the Pluracare grades find particular application in the cosmetic industry.
Pluracare F 127 is used as a solubilizer and emulsifier in a wide variety of areas from cosmetics to oral care products. At concentrations of about 20% in water it forms stable, clear, ringing gels in which a wide variety of ingredients can be incorporated. It is also used as a solubilizer.
Its HLB is in the range of 18 to 23.
CAS Number: 9003-11-6
Molecular Weight: ~ 12,600
Manufacture: BASF Corporation, 3000 Continental Drive, North, A specific example of Poloxamer used as a BMP carrier is found in Table 2. Table 2 demonstrates a method that has successfully caused BMP to be injected into animal subjects and create cartilage and bone growth. Specific results of this example include formation of a mature ossicle of bone with bone marrow cells in the middle of the injection site. The response was dose related.
From the above it can be appreciated that animal hair can be a carrier for BMP. Additionally Poloxamer 407 and similar compounds can be a carrier for BMP. Further Poloxamer 407 and similar compounds can be used as a BMP carrier in conjunction with the use of hair to make an artificial disk. The BMP in such an arrangement would create bone and cartilage on the outer periphery of the artificial disk in order to assist the artificial disk to bond with the upper and lower vertebral bodies which border the disk space. Additionally the BMP can assist the artificial disk to form an artificial nucleus. Additionally in another embodiment of the invention Poloxamer
407 and like compounds can be used as a film, a gel, or a fluid in order to prevent post surgical adhesions. This material is prepared as follows in a preferred embodiment in order to be positioned adjacent to a surgical site and be effective an anti-adhesion material. The method for preparing this compound is as follows: 25% gel of Poloxamer 407 prepared by weighing 25 grams of poloxamer crystal in a beaker and adding distilled H2O in a cold room at less than 3°C to bring the weight to 100 grams. Magnetic stirrer is used until a homogenous liquid is obtained. This will form a gel at room temperature.
Examples of BMP which can be used with the present invention can be obtained from a review of US Patent Nos. 4,563,489; 4,857,456; 4,795,804; all of which are incorporated herein by reference. Other examples for the promotion of bone growth can be found in the following US Patents all of which are incorporated herein by reference: U.S. Patent Nos. 5,531 ,791 and 5,484,601. Additionally polylactic acid can be used as a BMP carrier for the above disk replacement embodiments, as well as Gelfoam®, collagen, polyesther polymer mesh, composites of collagen and BMP, titanium fiber with BMP with or without non-collagenase proteins, polydioxanone, polγphosphazenes and BMP, ceramic collagen composite, expanded polytetrafluoroethylene barrier membranes, ethylene-vinyl acetate copolymers in methylene chloride (Elvax 40), composites of human fibrin, BMP/NCP in a polymethacrylate delivery system, sintered biodegradable b-tricalcium phosphate, composites of BMP and synthetic hydroxdyapatite mesh, hydroxy apatite adsorbed BMP, calcium sulphate, poiylactic acid polymer composites, composites of poly-D (lactide coglycolide, and composites of e- caprolactone, high molecular weight poiylactic acid homopolymers, composites of poly-2-hydroxyethyl methacrylate sponge, composites of polysulfone, polydioxanone, polyphosphazenes, cyanoacrylate, squalene, calcium glycerophosphoric acid, dextran, carbon, collagen type 1 , and methyl pyrrolidinone.
Hair as a Biologic Cosmetic Implant
Xenograft, homologous or autologous hair is an ideal cosmetic endoprosthesis 32 for breast, lip, muscle, nose 30, buttock, eyes chest.calves and thighs. The strength, immunologic compatibility, and modifiable characteristics of hair and keratin sulfate make it ideal as an adjunct to plastic surgery. Current implants are associated with stiffening and capsule formation after implantation resulting in less than natural cosmetic results. Extensive debate regarding autoimmune disorders as a result of silicone implants would be obviated since the recipients own hair protein is recognized by the their bodies own immune system. Various gels can be manufactured from hair protein, which have similarity in physical characteristics to connective tissue fat and hydrophilic gels. The tensile strength of hair fibers can be used for maintenance of structural integrity to match body contours.
As with hair utilized as an intervertebral disk implant, various treatments are available to modify hair in order to obtain desirable structural characteristics. These include heparin sulfate, hydrolysis, lithium bromide, hydroxylation, sulfating, alkalinization and acidification. Impregnation with morphogenetic growth factors can also be utilized.
Hair and Keratin Sulfate as a Biological Endoprosthesis for Blood Vessel Replacement
Autologous, homologous or xenograft hair is an ideal vascular graft 40 for arterial or venous replacement. It has the strength, compliance, immunological compatibility, flexibility, and ease of weaving into the appropriate structure. Autologous or allograft implants have minimal immunologic reactivity. The appropriate porosity of woven hair allows real endothelial growth. Hair can be woven or structured to have the compliance that is not present in the other grafts and can approximate normal vascular walls. The hair implant can be easily sutured to adjacent structures, because of the above characteristics. Patency of the hair vascular graft can be maintained. Hair can also be a part of the composite graft.
Hair as Joint Resurfacing or Meniscal Replacement
Autologous, allograft or xenograft hair is an appropriate implant for joint resurfacing and replacement for a meniscus. Hair can be woven and shaped into a different shape, size and porosity to fit human joints. It is immunologically compatible. It allows ingrowth of native cells into a woven structure. A hair graft 50 can easily be sutured to adjacent structures. It absorbs shock and stress well. Hair can be treated to form an elastomer. Hair can be fashioned into appropriate joint surfaces with reduced friction when compared to synthetic grafts. Hair as a Biological Endoprosthesis for Ligaments and Tendons
Autologous, homologous (allograft) or xenograft hair is an appropriate tendon or ligament graft 60. Hair can be woven into strong structures. It remains flexible. The hair graft can be easily sutured to adjacent structures. The porosity of woven hair allows ingrowth of native tissues. The immunological compatibility, strength, flexibility and modifiable characteristics of hair are ideal for ligament and tendon replacement.
Accordingly, the present invention can be used as a biologic disk, replacement, and/or structure.
Other features, aspects and objects of the invention can be obtained from a review of the figures and the claims.
It is to be understood that other embodiments of the invention can be developed and fall within the spirit and scope of the invention and claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US5137533 *||22 Nov 1991||11 Aug 1992||Giampapa Vincent C||Hair implantation structure|
|US5634945 *||2 Mar 1995||3 Jun 1997||Pernia; Luis R.||Biological filler and use of same|
|US5667961 *||6 Jun 1995||16 Sep 1997||Centre International De Recherches Dermatologigues Galderma (Cird Galderma)||Skin substitute|
|US5800545 *||4 Jun 1996||1 Sep 1998||Yamada; Shiro||Artificial hair for implantation and process for producing the same|
|US5944754 *||8 Nov 1996||31 Aug 1999||University Of Massachusetts||Tissue re-surfacing with hydrogel-cell compositions|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|EP1383444A2 *||20 Mar 2002||28 Jan 2004||Keraplast Technologies Ltd.||Implantable prosthetic or tissue expanding device|
|EP1383444A4 *||20 Mar 2002||13 Feb 2008||Keraplast Tech Ltd||Implantable prosthetic or tissue expanding device|
|US8652209||2 Jul 2012||18 Feb 2014||Clariance||Nuclear implant|
|US8740981||6 Apr 2009||3 Jun 2014||Clariance||Nuclear implant|
|International Classification||A61F2/30, A61L27/36, A61F2/00, A61F2/28, A61F2/08, A61F2/44|
|Cooperative Classification||A61F2310/00365, A61F2002/2817, A61F2/442, A61L2430/38, A61F2/08, A61L27/3658, A61F2/441, A61F2/30965, A61F2002/4495, A61L27/3687, A61F2210/0085, A61F2002/30583, A61F2002/444, A61F2310/00023, A61F2310/00293, A61L27/3604|
|European Classification||A61L27/36B, A61L27/36H2, A61L27/36F2D2, A61F2/44B, A61F2/44D|
|24 Aug 2000||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW
|24 Aug 2000||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
|18 Oct 2000||121||Ep: the epo has been informed by wipo that ep was designated in this application|
|9 Nov 2000||DFPE||Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)|
|13 Dec 2001||REG||Reference to national code|
Ref country code: DE
Ref legal event code: 8642
|17 Jul 2002||122||Ep: pct application non-entry in european phase|